Published Date: 24 Apr 2023
According to a recent study, bariatric surgery reduced incident cardiovascular disease and composite cardiovascular adverse outcomes by almost 50%.
Read Full NewsMRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.
Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.
Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.
A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.
1.
examining differences in the rates of breast reconstruction following mastectomies.
2.
AI catches one-third of interval breast cancers missed at screening
3.
The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.
4.
Lung cancer screening adherence rates decline annually after baseline screening
5.
Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024
1.
A Comprehensive Guide to Using an ABG Calculator for Accurate Diagnosis
2.
AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies
3.
HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians
4.
Unlocking the Mystery of Leukemia: Exploring New Treatments and Hope for Patients
5.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part V
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
4.
Navigating the Complexities of Ph Negative ALL - Part VIII
5.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation